Novo Nordisk A/S (NVO) Receives $52.00 Consensus Price Target from Brokerages

Share on StockTwits

Shares of Novo Nordisk A/S (NYSE:NVO) have received a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $52.00.

NVO has been the subject of several analyst reports. ValuEngine cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, November 26th. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, December 4th. Jefferies Financial Group reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Tuesday, December 11th. Finally, Cfra reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Friday, November 2nd.

Hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. grew its holdings in shares of Novo Nordisk A/S by 41.6% during the third quarter. PNC Financial Services Group Inc. now owns 699,142 shares of the company’s stock worth $32,958,000 after purchasing an additional 205,480 shares during the last quarter. Greenleaf Trust grew its holdings in shares of Novo Nordisk A/S by 7.3% during the third quarter. Greenleaf Trust now owns 27,910 shares of the company’s stock worth $1,316,000 after purchasing an additional 1,910 shares during the last quarter. Lenox Wealth Management Inc. grew its holdings in shares of Novo Nordisk A/S by 2.5% during the third quarter. Lenox Wealth Management Inc. now owns 92,644 shares of the company’s stock worth $4,367,000 after purchasing an additional 2,260 shares during the last quarter. Green Square Capital LLC grew its holdings in shares of Novo Nordisk A/S by 12.2% during the second quarter. Green Square Capital LLC now owns 11,177 shares of the company’s stock worth $515,000 after purchasing an additional 1,216 shares during the last quarter. Finally, Cozad Asset Management Inc. purchased a new position in shares of Novo Nordisk A/S during the second quarter worth about $341,000. 6.84% of the stock is currently owned by institutional investors.

Shares of NVO stock opened at $48.54 on Tuesday. Novo Nordisk A/S has a 1-year low of $41.23 and a 1-year high of $58.37. The firm has a market cap of $119.42 billion, a P/E ratio of 20.74, a price-to-earnings-growth ratio of 2.20 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, November 1st. The company reported $0.58 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.58. The firm had revenue of $4.31 billion for the quarter, compared to the consensus estimate of $4.11 billion. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. As a group, analysts predict that Novo Nordisk A/S will post 2.47 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Further Reading: Why is Cost of Capital Important?

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply